Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
股海静观陶
发表于 2024-5-13 09:44:09
1371
0
0
Southern Finance and Economics, May 13 (Xinhua) - Zaiding Pharmaceutical Hong Kong Stock Exchange announced that the National Medical Products Administration of China has approved the use of reprotinib for the treatment of ROS1 positive non-small cell lung cancer patients.
LogoMoney.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表LogoMoney.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表LogoMoney.com立场，且不构成建议，请谨慎对待。
猜你喜欢
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- Xiaomo bearish US stock market earnings season: Positive sentiment has been digested ahead of schedule, with most companies expecting a decline in profits
- Positive news keeps rising in major global markets, with multiple indices reaching historic highs!
- AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
- Incidence rate of lung cancer death in women is higher than that in men
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
-
美股市场：纽约股市三大股指4月30日涨跌不一。截至当天收盘，道琼斯工业平均指数比前一交易日上涨141.74点，收于40669.36点，涨幅为0.35%；标准普尔500种股票指数上涨8.23点，收于5569.06点，涨幅为0.15%；纳斯 ...- joey791216
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
美国总统特朗普近日在接受媒体采访时表示，他第二个任期不仅治理美国，也治理全世界。 特朗普于4月24日接受了《大西洋》（The Atlantic）月刊采访，这段专访于4月28日发布。 “第一次当总统时，我要做两 ...- lfancn
- 昨天 12:10
- 支持
- 反对
- 回复
- 收藏
-
东风有限回应武汉工厂关停事宜 据第一财经，4月29日，东风汽车有限公司证实，该公司武汉工厂目前正常运行，后续也不会关停。东风有限称，该公司将在东风与日产母公司的支持下平稳有序发展，持续加速向新能源 ...- king19831101
- 昨天 09:56
- 支持
- 反对
- 回复
- 收藏
-
4月29日凌晨，阿里巴巴开源新一代通义千问模型Qwen3(千问3)，参数量为DeepSeek-R1的三分之一，成本大幅下降。据称，该模型性能全面超越R1、OpenAI-o1等领先模型，登顶全球最强开源模型。 千问3是国内首个“ ...- 风雨中行走
- 前天 10:32
- 支持
- 反对
- 回复
- 收藏
